Author Correction: Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance (Nature, (2018), 553, 7686, (91-95), 10.1038/nature25015);Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance

Nature

Volumn 553, Issue 7686, 2018, Pages 91-95

  Zhang, Jinfang ^a   Bu, Xia ^a   Wang, Haizhen ^a   Zhu, Yasheng ^b   Geng, Yan ^a   Nihira, Naoe Taira ^a   Tan, Yuyong ^a,c   Ci, Yanpeng ^a,d   Wu, Fei ^a,e   Dai, Xiangpeng ^a   Guo, Jianping ^a   Huang, Yu Han ^a   Fan, Caoqi ^a,f   Ren, Shancheng ^b   Sun, Yinghao ^b   Freeman, Gordon J ^a   Sicinski, Piotr ^a   Wei, Wenyi ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d HARBIN INSTITUTE OF TECHNOLOGY   (China)

^e FUDAN UNIVERSITY   (China)

^f PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CULLIN; CULLIN 3; CYCLIN D; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; PALBOCICLIB; PROGRAMMED DEATH 1 RECEPTOR; SPECKLE TYPE POZ PROTEIN; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; FIZZY RELATED PROTEIN; FZR1 PROTEIN, HUMAN; NUCLEAR PROTEIN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROTEASOME; PROTEIN 14 3 3; REPRESSOR PROTEIN; SPOP PROTEIN, HUMAN;

CANCER; CELLS AND CELL COMPONENTS; DETECTION METHOD; DISEASE CONTROL; GENE; GENE EXPRESSION; IMMUNE RESPONSE; INHIBITOR; LIGAND; TUMOR;

ANAPHASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; GENE; GENE MUTATION; HEK293 CELL LINE; HEK293T CELL LINE; HELA CELL LINE; HS 578T CELL LINE; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; IN VIVO STUDY; MCF-7 CELL LINE; MDA-MB-231 CELL LINE; MEF CELL LINE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SPOP GENE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CYCLE; CELL LINE; CHEMISTRY; CYTOLOGY; IMMUNOLOGY; MALE; METABOLISM; NEOPLASM; PHOSPHORYLATION; PROSTATE TUMOR; PROTEIN STABILITY; TUMOR ESCAPE;

14-3-3 PROTEINS; ANIMALS; B7-H1 ANTIGEN; CDH1 PROTEINS; CELL CYCLE; CELL LINE; CULLIN PROTEINS; CYCLIN D; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; FEMALE; HUMANS; IMMUNOLOGIC SURVEILLANCE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; NEOPLASMS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROGRAMMED CELL DEATH 1 RECEPTOR; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; PROTEOLYSIS; REPRESSOR PROTEINS; TUMOR ESCAPE;

EID: 85040189345     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/s41586-019-1351-8     Document Type: Erratum

References (42)

1. Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv4 (2016).
2. Boussiotis, V. A. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N. Engl. J. Med. 375, 1767-1778 (2016).
3. Gotwals, P. et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat. Rev. Cancer 17, 286-301 (2017).
4. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56-61 (2015).
5. Mahoney, K. M., Rennert, P. D. & Freeman, G. J. Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14, 561-584 (2015).
6. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
7. Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293-12297 (2002).
8. Otto, T. & Sicinski, P. Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer 17, 93-115 (2017).
9. Casey, S. C. et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227-231 (2016).
10. Dorand, R. D. et al. Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science 353, 399-403 (2016).
11. Li, C. W. et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat. Commun. 7, 12632 (2016).
12. Lim, S. O. et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell 30, 925-939 (2016).
13. Schiff, P. B. & Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl Acad. Sci. USA 77, 1561-1565 (1980).
14. Malumbres, M. & Barbacid, M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 30, 630-641 (2005).
15. Hydbring, P., Malumbres, M. & Sicinski, P. Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat. Rev. Mol. Cell Biol. 17, 280-292 (2016).
16. Bates, S. et al. CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene 9, 71-79 (1994).
17. Lees, E., Faha, B., Dulic, V., Reed, S. I. & Harlow, E. Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner. Genes Dev. 6, 1874-1885 (1992).
18. Takaki, T. et al. Preferences for phosphorylation sites in the retinoblastoma protein of D-type cyclin-dependent kinases, Cdk4 and Cdk6, in vitro. J. Biochem. 137, 381-386 (2005).
19. Fry, D. W. et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427-1438 (2004).
20. Parry, D., Bates, S., Mann, D. J. & Peters, G. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J. 14, 503-511 (1995).
21. Lukas, J. et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375, 503-506 (1995).
22. Soucy, T. A. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732-736 (2009).
23. Genschik, P., Sumara, I. & Lechner, E. The emerging family of CULLIN3-RING ubiquitin ligases (CRL3s): cellular functions and disease implications. EMBO J. 32, 2307-2320 (2013).
24. Barbieri, C. E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689 (2012).
25. Cancer Genome Atlas Research. The molecular taxonomy of primary prostate cancer. Cell 163, 1011-1025 (2015).
26. Sato, Y. et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 45, 860-867 (2013).
27. Xu, J. et al. Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31. 2 and 19q13. 4. Nat. Genet. 44, 1231-1235 (2012).
28. Gan, W. et al. SPOP promotes ubiquitination and degradation of the ERG oncoprotein to suppress prostate cancer progression. Mol. Cell 59, 917-930 (2015).
29. da Fonseca, P. C. et al. Structures of APC/CCdh1with substrates identify Cdh1 and Apc10 as the D-box co-receptor. Nature 470, 274-278 (2011).
30. Goel, S. et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature 548, 471-475 (2017).
31. Dai, X. et al. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat. Med. 23, 1063-1071 (2017).
32. Wan, L. et al. The APC/C E3 ligase complex activator FZR1 restricts BRAF oncogenic function. Cancer Discov. 7, 424-441 (2017).
33. Gao, D. et al. Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat. Cell Biol. 11, 397-408 (2009).
34. Yu, Q. et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9, 23-32 (2006).
35. Sicinska, E. et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 4, 451-461 (2003).
36. Hamanishi, J. et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl Acad. Sci. USA 104, 3360-3365 (2007).
37. Wang, H. et al. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature 546, 426-430 (2017).
38. Wan, L. et al. APCCdc20 suppresses apoptosis through targeting Bim for ubiquitination and destruction. Dev. Cell 29, 377-391 (2014).
39. Kozar, K. et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 118, 477-491 (2004).
40. Choi, Y. J. et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell 22, 438-451 (2012).
41. Sicinski, P. et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82, 621-630 (1995).
42. Yu, Q. et al. Specific protection against breast cancers by cyclin D1 ablation. Nature 411, 1017-1021 (2001).